{"id":705148,"date":"2024-07-03T17:18:01","date_gmt":"2024-07-03T17:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=705148"},"modified":"2024-07-03T17:18:01","modified_gmt":"2024-07-03T17:18:01","slug":"metastatic-colorectal-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-colorectal-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_705148.html","title":{"rendered":"Metastatic Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1719982376.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Metastatic Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1719982376.jpeg\" alt=\"Metastatic Colorectal Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,<strong>&nbsp;&ldquo;Metastatic Colorectal Cancer Pipeline Insight 2024&rdquo;&nbsp;<\/strong>report provides comprehensive insights about&nbsp;<strong>130+ companies and 140+ pipeline drugs<\/strong>&nbsp;in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Explore our latest breakthroughs in Metastatic Colorectal Cancer Research. Learn more about our innovative pipeline today! @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Metastatic Colorectal Cancer Pipeline Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>July 2024:- AbbVie- A Phase 2, Randomized Study to Evaluate Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination With Fluorouracil, Folinic Acid, and Bevacizumab in Previously Treated Subjects With Unresectable Metastatic Colorectal Cancer. Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given in combination with Fluorouracil, Folinic Acid, and Bevacizumab to adult participants to treat unresctable metastatic colorectal cancer.<\/li>\n<li>June 2024:- Mirati Therapeutics Inc.- A Phase 1\/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1. This study will evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small molecule inhibitor of KRAS G12C.<\/li>\n<li>DelveInsight&#8217;s Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.<\/li>\n<li>The leading Metastatic Colorectal Cancer Companies such as Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A\/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A\/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.<\/li>\n<li>Promising Metastatic Colorectal Cancer Pipeline Therapies such as ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin\/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Stay informed about the cutting-edge advancements in Metastatic Colorectal Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Metastatic Colorectal Cancer Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic Colorectal Cancer Emerging Drugs Profile<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Adagrasib (MRTX849): Mirati Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRASG12C mutation. Adagrasib is being explored as a monotherapy as well as in combination with other anticancer drugs. The goal is to optimize efficacy and prevent treatment resistance, ensuring these potentially promising combination therapies can help patients throughout the course of their treatment journey. Extensive preclinical studies showed that combining adagrasib with a broad range of therapies, including PD-1, SHP2, Pan-EGFR, CDK 4\/6, and SOS1 inhibitors, resulted in even more robust anti-tumor activity.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>QL-1203: Qilu Pharmaceutical<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">QL-1203, is an investigational drug being developed by Qilu Pharmaceutical. QL-1203, acts as an epidermal growth factor receptor modulator. It belongs to the class of monoclonal antibodies. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Metastatic colorectal cancer.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ZN-c3: Zentalis Pharmaceuticals<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">ZN-c3 is an oral inhibitor of WEE1 in development for the treatment of advanced solid tumors. The inhibition of WEE1, a DNA damage response protein, aims to generate sufficient DNA damage in cancer cells, causing cell death, thereby preventing tumor growth and potentially causing tumor regression. Zentalis is currently conducting a Phase 1\/2 clinical trial in patients with Metastatic Colorectal Cancer. In addition, the Company is also conducting a Phase 1b trial evaluating ZN-c3 in combination with chemotherapy in patients with advanced ovarian cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about Metastatic Colorectal Cancer Drugs opportunities in our groundbreaking Metastatic Colorectal Cancer Research and development projects @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Metastatic Colorectal Cancer Unmet Needs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Intravenous<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical.<\/li>\n<li>Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Metastatic Colorectal Cancer Products have been categorized under various Molecule types such as<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Monoclonal Antibody<\/li>\n<li>Peptides<\/li>\n<li>Polymer<\/li>\n<li>Small molecule<\/li>\n<li>Gene therapy<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Discover the latest advancements in Metastatic Colorectal Cancer Treatment by visiting our website. Stay informed about how we&#8217;re transforming the future of oncology disease @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspectives<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Metastatic Colorectal Cancer Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A\/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A\/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Metastatic Colorectal Cancer Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- Global<\/li>\n<li>Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono\/Combination<\/li>\n<li>Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li>Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A\/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A\/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.<\/li>\n<li>Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin\/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Colorectal Cancer Pipeline on our website @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Metastatic Colorectal Cancer Drugs and Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Metastatic colorectal cancer: Overview<\/p>\n<p style=\"text-align: justify;\">4. Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Metastatic colorectal cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">7. In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">8. Metastatic colorectal cancer Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">9. Late Stage Products (Phase III)<\/p>\n<p style=\"text-align: justify;\">10. MRTX849: Mirati Therapeutics<\/p>\n<p style=\"text-align: justify;\">11. Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">12. Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">13. AK-112: Akeso Biopharma<\/p>\n<p style=\"text-align: justify;\">14. Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">15. Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">16. SY 5609: Syros Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\">17. Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">18. Preclinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">19. Drug name: Company name<\/p>\n<p style=\"text-align: justify;\">20. Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">21. Inactive Products<\/p>\n<p style=\"text-align: justify;\">22. Metastatic colorectal cancer Key Companies<\/p>\n<p style=\"text-align: justify;\">23. Metastatic colorectal cancer Key Products<\/p>\n<p style=\"text-align: justify;\">24. Metastatic colorectal cancer- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">25. Metastatic colorectal cancer- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">26. Metastatic colorectal cancer- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">27. Metastatic colorectal cancer Analyst Views<\/p>\n<p style=\"text-align: justify;\">28. Metastatic colorectal cancer Key Companies<\/p>\n<p style=\"text-align: justify;\">29. Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=metastatic-colorectal-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=metastatic-colorectal-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&rsquo;s,&nbsp;&ldquo;Metastatic Colorectal Cancer Pipeline Insight 2024&rdquo;&nbsp;report provides comprehensive insights about&nbsp;130+ companies and 140+ pipeline drugs&nbsp;in Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-colorectal-cancer-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight_705148.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-705148","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/705148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=705148"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/705148\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=705148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=705148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=705148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}